ProCE Banner Activity

Antiplatelet Therapy, Bleeding Risk, and Reversal Strategies: Expert Answers to Your Questions

Clinical Thought

Answers to questions from healthcare professionals, asked during a live satellite symposium held at an annual stroke conference in February 2025, are provided regarding the management of patients receiving antiplatelet therapy after a stroke. These responses provide guidance on how to implement the latest evidence on antiplatelet therapy, bleeding risk, and reversal among patients with acute stroke. 

Released: March 11, 2025

Expiration: March 10, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from SERB Pharmaceuticals.

SERB Pharmaceuticals

Disclosure

Primary Author

Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI

Director of Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI: advisor: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, E-Star Biotech, Janssen, McKinsey, Merck, NirvaMed, Novo Nordisk, Stasys, Tourmaline Bio; individual publicly traded stock/stock options: Angiowave, Bristol Myers Squibb; consultant: Corcept Therapeutics, GlaxoSmithKline, Hims, SFJ, Summa Therapeutics, Youngene; data and safety monitoring committees: Acesion Pharma, Boston Scientific, Contego Medical, Daiichi Sankyo, Novartis; honoraria: Bayer,CSL Behring, Ferring; researcher: 89 Bio, Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday, Ferring, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene; other financial or material support: Cleerly.